M&A Deal Summary

Polyplus Acquires Xpress Biologics

On December 7, 2022, Polyplus acquired life science company Xpress Biologics from ArchiMed

Acquisition Highlights
  • This is Polyplus’ 1st transaction in the Life Science sector.
  • This is Polyplus’ 1st transaction in Belgium.

M&A Deal Summary

Date 2022-12-07
Target Xpress Biologics
Sector Life Science
Buyer(s) Polyplus
Sellers(s) ArchiMed
Deal Type Add-on Acquisition

Target

Xpress Biologics

Milmort, Belgium
Xpress Biologics is a developer of expression systems and manufacturing processes for the production of plasmid DNA and protein therapeutics. Xpress Biologics was founded in 2014 and is based in Milmort, Belgium.

Search 214,107 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Polyplus

Illkirch, France

Category Company
Founded 2001
Sector Life Science
DESCRIPTION

Polyplus is a biotechnology company that supports Gene and Cell therapy, biologics manufacturing, and life science research with innovative nucleic acid transfection solutions. Polyplus was founded in 2001 and is based in Illkirch, France.


DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
Country: Belgium M&A 1 of 1
Year: 2022 M&A 1 of 1

Seller(S) 1

SELLER

ArchiMed

Investor Investor Investor Investor Investor


Category Private Equity Firm
Founded 2014
PE ASSETS 8.0B EUR
Size Mega
Type Sector Focused
DESCRIPTION

ArchiMed is a specialist French private equity firm focused on buyouts of and growth capital investments in European healthcare-oriented companies. The Firm looks to invest €10 million to €1 billion per transaction and specifically targets companies in the public health, care and wellness, biotech, and medical technology segments of the healthcare industry. ArchiMed was formed in 2014 and is headquartered in Lyon.


DEAL STATS #
Overall 7 of 9
Sector: Life Science M&A 1 of 2
Type: Add-on Acquisition M&A Deals 6 of 8
Country: Belgium M&A 1 of 1
Year: 2022 M&A 5 of 5
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-12-02 Micromed

Treviso, Italy

Micromed is a medical device company delivering solutions in Neurophysiology to over 78 countries worldwide. Partnering with hospitals, sleep labs, and research centers on a global scale, the company manufactures and markets high-quality, cost-effective, and clinically relevant neurodiagnostic hardware and software to neurologists, clinicians, and researchers for use on adult and pediatric patients. Its product portfolio ranges from Routine, Ambulatory, and Video EEG to electrocorticography (ECoG), stereoelectroencephalography (SEEG), PSG, evoked potentials (EP), EMG and ICU multimodal monitoring solutions for clinical and research. Micromed was formed in 1982 and is based in Treviso, Italy.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2023-03-09 WiQo

Milan, Italy

WiQo focuses on the development, manufacturing, and distribution of non-invasive and non-surgical skin health medical devices with scientifically validated efficacy and safety. WiQo was founded in 1994 and is based in Milan, Italy.

Buy -